OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
00079055

Chengdu huasun technology group Inc LTD

PharmaceuticalsVerified

Chengdu Huasun Technology Group Inc LTD has a debt-to-equity ratio of 0.53 and a current ratio of 0.78, indicating moderate leverage and limited short-term liquidity. The company reported negative operating income of CNY -337.1 million and a net loss of CNY -320.4 million, with a return on equity of -44.77% and a return on assets of -23.07%. These metrics suggest the company is underperforming relative to industry norms, particularly in profitability and capital efficiency. The company's operating cash flow of CNY 85.4 million contrasts with a free cash flow of CNY -376.7 million, driven by capital expenditures of CNY -63.0 million. This negative free cash flow indicates that the company is not generating sufficient cash to fund its operations and investments without external financing. The liquidity risk is further compounded by the fact that net cash is negative after subtracting total debt. Segment and geographic exposure data are not available in the provided dataset, but the company's revenue concentration and geographic diversification remain key areas to monitor for future analysis. The absence of segment-level data limits the ability to assess the performance of individual product lines or geographic regions. The company's growth trajectory is uncertain, as no specific revenue growth or decline figures are provided for the current or next fiscal year. However, the negative net income and operating income suggest a challenging operating environment. The company's capital expenditures and free cash flow indicate a need for careful financial planning to sustain operations and fund future growth. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential challenges in meeting short-term obligations. The dilution risk is low, suggesting that the company is not currently issuing shares at a rate that would significantly dilute existing shareholders. Recent events, including filings and transcripts, are not detailed in the provided dataset. However, the company's financial performance and liquidity position suggest that it may be under pressure to improve its operational efficiency and cash flow generation. The absence of recent events data limits the ability to assess the company's strategic direction and management response to current challenges.

30-day price · 000790+0.12 (+2.9%)
Low$3.79High$4.65Close$4.25As of15 May, 00:00 UTC
Profile
CompanyChengdu huasun technology group Inc LTD
Ticker000790.SZ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Chengdu Huasun Technology Group Inc LTD is a pharmaceutical company engaged in the research, development, production, and sale of pharmaceutical products.

Classification. The company is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry with a confidence level of 0.92.

Chengdu Huasun Technology Group Inc LTD has a debt-to-equity ratio of 0.53 and a current ratio of 0.78, indicating moderate leverage and limited short-term liquidity. The company reported negative operating income of CNY -337.1 million and a net loss of CNY -320.4 million, with a return on equity of -44.77% and a return on assets of -23.07%. These metrics suggest the company is underperforming relative to industry norms, particularly in profitability and capital efficiency. The company's operating cash flow of CNY 85.4 million contrasts with a free cash flow of CNY -376.7 million, driven by capital expenditures of CNY -63.0 million. This negative free cash flow indicates that the company is not generating sufficient cash to fund its operations and investments without external financing. The liquidity risk is further compounded by the fact that net cash is negative after subtracting total debt. Segment and geographic exposure data are not available in the provided dataset, but the company's revenue concentration and geographic diversification remain key areas to monitor for future analysis. The absence of segment-level data limits the ability to assess the performance of individual product lines or geographic regions. The company's growth trajectory is uncertain, as no specific revenue growth or decline figures are provided for the current or next fiscal year. However, the negative net income and operating income suggest a challenging operating environment. The company's capital expenditures and free cash flow indicate a need for careful financial planning to sustain operations and fund future growth. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, indicating potential challenges in meeting short-term obligations. The dilution risk is low, suggesting that the company is not currently issuing shares at a rate that would significantly dilute existing shareholders. Recent events, including filings and transcripts, are not detailed in the provided dataset. However, the company's financial performance and liquidity position suggest that it may be under pressure to improve its operational efficiency and cash flow generation. The absence of recent events data limits the ability to assess the company's strategic direction and management response to current challenges.
Key takeaways
  • Chengdu Huasun Technology Group Inc LTD is experiencing significant financial distress, with negative operating and net income.
  • The company's liquidity position is weak, as indicated by a current ratio of 0.78 and negative free cash flow.
  • The debt-to-equity ratio of 0.53 suggests moderate leverage, but the negative net cash position after subtracting total debt is a key liquidity risk.
  • The company's profitability metrics, including return on equity and return on assets, are well below acceptable levels.
  • The absence of segment and geographic data limits the ability to assess the company's diversification and risk exposure.
  • The company's growth trajectory is uncertain, and it may need to implement cost-cutting measures or secure additional financing to sustain operations.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$545.5M
Gross profit$252.1M
Operating income-$337.1M
Net income-$320.4M
R&D
SG&A
D&A
SBC
Operating cash flow$85.4M
CapEx-$63.0M
Free cash flow-$376.7M
Total assets$1.39B
Total liabilities$673.4M
Total equity$715.7M
Cash & equivalents
Long-term debt$379.0M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$715.7M
Net cash-$379.0M
Current ratio0.8
Debt/Equity0.5
ROA-23.1%
ROE-44.8%
Cash conversion-27.0%
CapEx/Revenue-11.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric000790Activity
Op margin-61.8%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin-58.7%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin46.2%19.7% medp25 19.7% · p75 39.8%top quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-11.6%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity53.0%71.3% medp25 19.0% · p75 91.7%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 10:28 UTC#7e8ac8a4
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 11:34 UTCJob: 434fdcc5